After finishing at $14.85 in the prior trading day, Teladoc Health Inc (NYSE: TDOC) closed at $14.33, down -3.50%. In other words, the price has decreased by -$0.52 from its previous closing price. On the day, 5934845 shares were traded.
Ratios:
Our goal is to gain a better understanding of TDOC by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.13 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.07. For the most recent quarter (mrq), Quick Ratio is recorded 3.39 and its Current Ratio is at 3.46. In the meantime, Its Debt-to-Equity ratio is 0.68 whereas as Long-Term Debt/Eq ratio is at 0.68.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on February 29, 2024, initiated with a Overweight rating and assigned the stock a target price of $22.
On February 26, 2024, Leerink Partners started tracking the stock assigning a Market Perform rating and target price of $17.
DA Davidson Downgraded its Buy to Neutral on January 17, 2024, whereas the target price for the stock was revised from $33 to $22.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 25 ’24 when Geshuri Arnnon sold 7,500 shares for $15.06 per share. The transaction valued at 112,950 led to the insider holds 38,470 shares of the business.
Trencher Daniel sold 1,000 shares of TDOC for $15,180 on Mar 18 ’24. The CHIEF STRATEGY OFFICER now owns 27,192 shares after completing the transaction at $15.18 per share. On Mar 05 ’24, another insider, Turitz Andrew, who serves as the EVP, CORPORATE DEVELOPMENT of the company, sold 5,647 shares for $14.53 each. As a result, the insider received 82,051 and left with 33,782 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TDOC now has a Market Capitalization of 2.39B and an Enterprise Value of 2.86B. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.92 while its Price-to-Book (P/B) ratio in mrq is 1.03. Its current Enterprise Value per Revenue stands at 1.10 whereas that against EBITDA is 18.59.
Stock Price History:
Over the past 52 weeks, TDOC has reached a high of $30.41, while it has fallen to a 52-week low of $14.29. The 50-Day Moving Average of the stock is 17.15, while the 200-Day Moving Average is calculated to be 20.05.
Shares Statistics:
The stock has traded on average 4.68M shares per day over the past 3-months and 3.64M shares per day over the last 10 days, according to various share statistics. A total of 166.66M shares are outstanding, with a floating share count of 165.21M. Insiders hold about 1.10% of the company’s shares, while institutions hold 77.39% stake in the company. Shares short for TDOC as of Mar 15, 2024 were 20.28M with a Short Ratio of 4.34, compared to 20.51M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 12.14% and a Short% of Float of 13.79%.
Earnings Estimates
Its stock is currently analyzed by 21 different market analysts. On average, analysts expect EPS of -$0.46 for the current quarter, with a high estimate of -$0.28 and a low estimate of -$0.54, while EPS last year was -$0.42. The consensus estimate for the next quarter is -$0.3, with high estimates of -$0.17 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$0.73 and -$1.38 for the fiscal current year, implying an average EPS of -$1.03. EPS for the following year is -$0.7, with 20 analysts recommending between -$0.16 and -$1.17.
Revenue Estimates
24 analysts predict $637.44M in revenue for the current quarter. It ranges from a high estimate of $645.2M to a low estimate of $632.57M. As of the current estimate, Teladoc Health Inc’s year-ago sales were $618.31M, an estimated increase of 3.10% from the year-ago figure. For the next quarter, 24 analysts are estimating revenue of $663.06M, an increase of 2.10% less than the figure of $3.10% in the same quarter last year. There is a high estimate of $678.31M for the next quarter, whereas the lowest estimate is $642.6M.
A total of 26 analysts have provided revenue estimates for TDOC’s current fiscal year. The highest revenue estimate was $2.69B, while the lowest revenue estimate was $2.64B, resulting in an average revenue estimate of $2.67B. In the same quarter a year ago, actual revenue was $2.6B, up 2.50% from the average estimate. Based on 25 analysts’ estimates, the company’s revenue will be $2.76B in the next fiscal year. The high estimate is $2.83B and the low estimate is $2.72B. The average revenue growth estimate for next year is up 3.70% from the average revenue estimate for this year.
